Naturally Splendid (NSP.V) has provided an update regarding a Health Canada approved clinical trial and strategic outlook for the development of Cavaltinib™.

“We have been working with Franco and Biologic Pharmamedical Research for over two years and are confident that the patented technology that is the foundation to CavaltinibTM has great potential as a treatment for COVID as well as additional applications for other respiratory and auto-immune conditions. Our initial focus is for a COVID treatment. However, we believe the results from this clinical study will also provide valuable data on the effectiveness of Cavaltinib in other applications,” stated Naturally Splendid CEO Mr. Craig Goodwin.

The clinical trial will be run through Plasm Pharmaceutical, a Joint Venture (JV) between Biologic Pharmamedical (Biologic) and Naturally Splendid. Wait, I thought Naturally Splendid was a plant-based foods company! Well my astute reader, Naturally Splendid joined the race for a COVID-19 treatment awhile ago, specifically on May 19, 2020. The Company teamed up with Biologic to support its phase two clinical trials in an attempt to develop a potential treatment. Cavaltinib™ is the product of their work and it was just recently approved for phase two clinical trials by Health Canada.

“The treatment offered by Naturally Splendid is an amplified variant of one of Biologic’s existing technology. This patented tech when taken in capsule form could reduce or eliminate the need for infected patents to congregate in hospitals or clinics for infusions or other treatments. The capsule delivery system, if it works, would increase the effectiveness of treatment at a fraction of the cost, up to and including eliminating the need for hospitalization, and provide more safety for our at-risk front line medical staff,” stated Equity Guru’s Joseph Morton.

With this in mind, Cavaltinib™ has been recognized as a treatment candidate by Health Canada which is already a significant accomplishment. The objective of the clinical trials is to produce concrete evidence supporting the effectiveness of Cavaltinib™ as a treatment option for high-risk patients susceptible to COVID-19. Due to the variability of the virus, infection rates and cases of morbidity are still climbing, making the need for alternative treatments necessary.


The clinical trials will also serve as an opportunity to study the potential of Cavaltinib™ for use in other treatments. Cavaltinib™ shows promise for a variety of treatments pertaining to ulcerative colitis, Crohn’s disease, asthma, COPD, arthritis and other autoimmune and autoinflammatory conditions. With this in mind, Cavaltinib™ appears to be flexible in its applications, however, current clinical trials are focused on developing Cavaltinib™ into a reliable treatment for COVID-19. Research in the area of auto-immune and anti-inflammatory indications will ensue following the clinical studies for COVID-19.


Due to its versatile nature, Cavaltinib™ will likely be profitable for Naturally Splendid even after the pandemic has passed. The Company has also been performing quite well in the hempseed market, seeing considerable growth in the past year. Moreover, Naturally Splendid remains a low risk investment and may be worth keeping on your watchlist.


Keep in mind, Naturally Splendid has made it explicitly clear that it is not claiming to have the ability to eliminate COVID-19 at this time.

Naturally Splendid’s stock price opened at $0.065 today and currently remains the same.

Written By:

Kieran Robertson

Kieran Robertson is an experienced writer with a passion for technology, esports, and video games. He graduated from the University of Western Ontario with a Major in English Language and Literature. After graduating, Kieran worked as a freelance writer, managing his own blog and volunteering for La Maza Magazine, a magazine startup focused on collaborating with photographers, writers, models, and designers.

More By This Author
clinical trials
Naturally Splendid
phase 2
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments